Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Teen depression study aims to predict who will respond to antidepressants

NCT ID NCT05329441

Knowledge-focused Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is recruiting 160 depressed teens aged 14-21 to understand how stress affects inflammation and brain chemistry. Participants will undergo a mild stress test and then take either fluoxetine or escitalopram for 12 weeks. Researchers will track who responds to treatment and follow participants for 18 months to see how their depression changes over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which depressed teens will benefit from common antidepressants, leading to more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear predictors, and results may not apply to all teens or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adolescents presenting to school counseling centers, community clinics, and/or medical centers (primary care, psychiatry, etc)

Ages

14 to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All sexes and genders * All ethnicities * Ages 14-21 * Postpubertal (Tanner stage \> 3) * No medications that will interfere with the study (including antidepressants, mood stabilizers, hormone supplements, steroids, etc.) for at least 2-6 weeks (depending on exact medication) * Currently being seen by a clinician who will treat the participant with fluoxetine or escitalopram * The ability to provide assent, understand, and complete all study procedures * Caregiver consent (if applicable) Exclusion Criteria: * Primary mental health diagnosis other than a depressive disorder according to DSM-V * Any contraindications to MRI scanning, phlebotomy, or SSRI treatment * Stimulant usage * A concussion within the last 6 weeks or any lifetime concussion with loss of consciousness for at least 10 minutes * Any inflammatory conditions or use of anti-inflammatory medications that may influence study findings * Any major neurological or developmental disorders which could impact the participant's ability to comply with study procedure * Meeting for current or lifetime criteria of mania or psychosis, diagnosis of bipolar disorder, or any substance use disorders * First-degree relative with current, past, or suspected mania or psychosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression in adolescence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression in adolescence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.